Coronary Artery Disease Clinical Trial
Official title:
A Study to Compare the Effects of Sarpogrelate Sustained Release /Aspirin Combination Therapy Versus Aspirin on Blood Viscosity in the Patients With Peripheral Arterial Disease and Coronary Artery Disease; A Prospective, Randomized, Parallel, Open-Label, Single-center, Phase IV Clinical Trial
This study is to compare the effects of sarpogrelate sustained release /aspirin combination therapy versus aspirin on blood viscosity in the patients with peripheral arterial disease and coronary artery disease
Status | Recruiting |
Enrollment | 60 |
Est. completion date | February 28, 2024 |
Est. primary completion date | February 28, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: 1. Both man and woman who is over 19 years old 2. Identified as 10-75% of Stenosis in Coronary Angiography or Coronary CTA(Coronary computed tomography angiography) 3. Patients who diagnosed with peripheral artery disease or has symptoms 4. Written informed consent Exclusion Criteria: 1. Patients who is scheduled surgery due to coronary artery disease or cerebral infarction disease. 2. Patients who have taken aspirin within two weeks before randomization 3. Patients who need antiplatelet or anticoagulant medication except Aspirin 4. Confirmed below results at screening - Hemoglobin <13g/dL - Platelet <60,000/µL - Severe kidney disease patient with eGFR(estimated Glomerular Filtration Rate) <30 mL/min/1.73 m2 (CKD-EPI) 5. Patients with a history of cerebrovascular and cardiovascular complications (brain infarction, transient cerebral ischemic seizures, myocardial infarction, unstable angina, coronary artery bypass graft, percutaneous coronary artery intervention) within the last six months 6. Patients with bleeding 7. Pregnant or lactating women 8. Those participating in other clinical trials for investigational products 9. Patients deemed to be ineligible to participate in the trial by investigator |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | The Catholic University of Korea Uijeongbu St. Mary's Hospital | Uijeongbu | Gyeonggi-do |
Lead Sponsor | Collaborator |
---|---|
Yuhan Corporation |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline to week 12 in Blood Viscosity(cP, centipoise) measured by the blood viscometer | Baseline/Week 12 | ||
Secondary | Change from baseline to week 4 in Blood Viscosity(cP, centipoise) measured by the blood viscometer | Baseline/Week 4 | ||
Secondary | Change from baseline to week 4, 12 in Erythrocyte Deformability(elogation index at 3Pa) measured by Microfluidic Scanning Method | Baseline/Week 4/Week 12 | ||
Secondary | Change from baseline to week 4, 12 in Erythrocyte Aggregation(critical shear stress) measured by Microfluidic Scanning Method | Baseline/Week 4/Week 12 | ||
Secondary | Change from baseline to week 4, 12 in FMD(Flow Mediated Dilation) by Endothelium-dependent vasodilation measurement | Baseline/Week 4/Week 12 | ||
Secondary | Rate of change from baseline to week 4, 12 in tODI(tissue oxygen delivery index) | Baseline/Week 4/Week 12 | ||
Secondary | Proportion of subjects who tODI(tissue oxygen delivery index) have improved by 20% or more | Week 12 | ||
Secondary | Rate of change from baseline to week 4, 12 in Lipid profile | Baseline/Week 4/Week 12 | ||
Secondary | Rate of change from baseline to week 4, 12 in FPG(Fasting Plasma Glucose) | Baseline/Week 4/Week 12 | ||
Secondary | Rate of change from baseline to week 4, 12 in HOMA-IR(Homeostatic Model Assessment for Insulin Resistance) | Baseline/Week 4/Week 12 | ||
Secondary | Rate of change from baseline to week 4, 12 in hs-CRP(high sensitivity C-Reactive Protein) | Baseline/Week 4/Week 12 | ||
Secondary | Change from baseline to week 12 in SF-36(Questionnaire for Medical Outcome Short Form Health Survey, 36-Item) | Baseline/Week 12 | ||
Secondary | Change from baseline to week 12 in VAS(Visual Analogue Scale) | Baseline/Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |